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Background Antibody-mediated rejection (AMR) remains a major management challenge in heart transplantation given the com-
plexity of pathological diagnosis and dearth of evidence for effective management. Eculizumab, an anti-C5 monoclo-
nal antibody which inhibits terminal complement activation, has been reported to decrease early AMR in sensitized
renal transplant recipients.
...................................................................................................................................................................................................
Case summary We report a case of a 29-year-old gentleman with chronic AMR 8 years after heart transplantation, manifesting as
significant graft dysfunction. Donor-specific antibodies to DQ7 were found to be causative. Antibody-mediated re-
jection was managed with quadruple oral immunosuppressive therapy (mycophenolate, prednisolone, everolimus,
and tacrolimus) as well as a sequence of broad-spectrum immunological therapies; intravenous (IV) methylpredni-
solone, plasmapheresis, IV immunoglobulin, rituximab, bortezomib, tocilizumab, and splenic irradiation. No treat-
ment had a sustained impact on donor-specific anti-HLA antibodies (DSAs) or graft function. After testing showed
the DQ7 antibodies were complement-binding, a trial of eculizumab was started. This improved DSAs somewhat,
and improved graft function and New York Heart Association functional class substantially. The patient was relisted
for heart transplantation and successfully retransplanted in March 2018. Specifically, the new organ and recipient
were matched at DQ7. After discontinuation of eculizumab, the patient has remained healthy and well, with normal
graft function 28 months after retransplantation.
...................................................................................................................................................................................................
Discussion To the best of our knowledge, this is the first case of chronic AMR in a heart transplant patient, successfully stabi-
lized with eculizumab and bridged to retransplantation.
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Antibody-mediated rejection (AMR) remains a major management
challenge in heart transplantation given the complexity of pathologic-
al diagnosis and dearth of evidence for effective management strat-
egies. Eculizumab, an anti-C5 monoclonal antibody which inhibits
terminal complement activation, has been reported to decrease early
AMR in sensitized renal transplant recipients1 although it failed to
prevent chronic AMR in renal transplant recipients with persistently
high levels of donor-specific anti-HLA antibodies (DSAs).2
Timeline
Case presentation
We report a case of a 29-year-old male, who underwent heart trans-
plantation for dilated cardiomyopathy, bridged to transplant with left
ventricular assist device (LVAD) and transplanted semi-urgently due
to LVAD-related sepsis. At the time of transplantation, T-cell cross-
match was negative, but B-cell crossmatch was weakly positive. Low
titre human leukocyte antigen (HLA) antibodies were detected
including DQ7 (MFI 628). Induction immunosuppression included
basiliximab at Day 0 and Day 4 and three doses of 125 mg intraven-
ous (IV) methylprednisolone. This was followed by 1 mg/kg per day
oral prednisolone in divided doses weaning by 5 mg/day. Additionally,
the patient received cyclosporin and mycophenolate from Day 1
post-transplant.
His post-transplant course was complicated by presentation with
recurrent exertional dyspnoea, with clinical findings consistent with
heart failure. This was diagnosed as multiple episodes of acute cellular
and humoral rejection with graft dysfunction. Graft dysfunction with
severely impaired left ventricular systolic function (estimated ejection
fraction 30–35%) was first noted in at 2.5 years post-transplant, with
concomitant moderate right ventricular dysfunction. Three episodes
of acute cellular rejection (Grade 3A/2R) requiring treatment
occurred, starting at 12 months post-transplant, and four episodes of
AMR (pAMR Grade 2) started at 2.5 years post-transplant. Multiple
Classes I and II DSAs were detected, including to complement-bind-
ing DQ7 with mean fluorescence intensity (MFI) when first measured
2.5 years after transplantation. Maintenance therapy was quadruple
oral immunosuppressive therapy (mycophenolate, prednisolone,
everolimus, and tacrolimus) from 12 months onwards. Treatment for
AMR included multiple cycles of methylprednisolone, plasmapher-
esis, and IV immunoglobulin (IVIG), with adjuvant rituximab (375 mg/
m2 via IV infusion), bortezomib (3 mg subcutaneously), splenic irradi-
ation (350 Gy in twice weekly 50 Gy fractions) in combination with
further rituximab and tocilizumab (800 mg via IV infusion monthly) in
order of escalation, none of which produced a sustained response.
Figure 1 details the timeline and treatment course. There was persist-
ent moderate left ventricular systolic dysfunction (ejection fraction
35–40%), elevated filling pressures, and cardiac index of 2.0 L/min/m2
coinciding with functional class (FC) III–IV heart failure symptoms.
Coronary angiography was performed at 5 and 6 years after trans-
plantation, showed allograft vasculopathy with a chronically occluded
right coronary artery and minor irregularities of the left coronary sys-
tem, not amenable to revascularization.
Donor-specific anti-HLA antibodies to DQ7 were persistently ele-
vated with strongly positive C1q testing. It was decided to treat with
November 2009 Left ventricular assist device as bridge to transplantation for dilated cardiomyopathy
October 2010 Orthotopic heart transplantation
October 2011 First episode late cellular rejection, treated with intravenous (IV) methylprednisolone
December 2011 Second episode cellular rejection, treated with PO prednisolone pulse
January 2012 Third episode cellular rejection, treated with PO prednisolone pulse
May 2013 First episode antibody-mediated rejection (AMR), presenting with graft dysfunction and AV block, treated with apheresis,
IV immunoglobulin (IVIG), IV methylprednisolone, and bortezomib
December 2016 Second episode AMR, treated with apheresis, IVIG, IV methylprednisolone, and rituximab
May 2017 Third episode AMR, treated with apheresis, IVIG, splenic irradiation, and rituximab
August 2017 Fourth presentation with AMR, treated with apheresis, IVIG, and tocilizumab without clinical improvement, followed by se-
cond round of apheresis and IVIG with initiation of eculizumab
November 2017 Listed for re-do heart transplantation
March 2018 Retransplanted, with specific matching at DQ7, concomitant thymectomy
April 2018–July 2020 Normal graft function, no episodes of rejection
Learning points
• Antibody-mediated rejection (AMR) in cardiac transplantation is difficult to diagnose.
• Treatments for AMR are broad spectrum in approach.






















































































a loading regimen of eculizumab (1200 mg on Day 1, 900 mg on Day
2, and 900 mg on Weeks 2, 3, and 4), after five further plasma
exchanges, and fortnightly 1200 mg eculizumab thereafter. Given the
extensive immunosuppression regimen, prophylaxis with itracon-
azole, valganciclovir, and amoxicillin was used for fungal, cytomegalo-
virus, and encapsulated bacteria prophylaxis, respectively.
Prophylactic treatment was effective in protecting against infection,
and this patient suffered no infective complications of the aggressive
immunosuppressive strategy undertaken.
After initiation of eculizumab, ejection fraction improved to 45%
and heart failure symptoms reduced to FC II. The MFI for DQ7 initial-
ly dropped to <10 000 but slowly trended upward. Despite this, he
experienced the first sustained improvement in heart failure symp-
toms and graft function in over 3 years. However, persistent diastolic
dysfunction and restrictive physiology were noted at
echocardiography.
The decision for relisting was taken after clinical stabilization.
Given that ongoing diastolic dysfunction and restrictive physiology
led to ongoing New York Heart Association functional Class II symp-
toms and advanced coronary allograft vasculopathy, felt unlikely to
respond to immunosuppressive therapy, as well as his young age and
potential infective implications of long-term eculizumab, the patient
was relisted for transplantation, and successfully transplanted 8 years
following initial transplantation and 5 months after commencing eculi-
zumab. Concomitant thymectomy was performed at retransplanta-
tion. Both T and B cell crossmatch were negative, but he had
persistent strong DSAs. Notably, the recipient and organ were
matched at DQ7.
He underwent pre-emptive plasmapheresis at the time of trans-
plantation and maintained on fortnightly 1200 mg eculizumab empir-
ically for 3 months post-retransplantation, as well as usual post-
transplant quadruple immunosuppressive regimen including prednis-
olone, tacrolimus, mycophenolate, and everolimus. Now, almost
3 years after transplant, there have not been any episodes of rejection
and graft function is normal. As part of routine protocol, we contin-
ued to monitor DSAs following the second allograft transplant coin-
ciding with endomyocardial biopsy. We surveilled DSAs up to 1 year
after transplantation, at weekly for the first month and then fortnight-
ly from months 2–3, monthly at months 4–6, and then at 9 and
12 months. Because DQ7 testing is part of routine Luminex monitor-
ing after transplant, continued monitoring has been performed but
given matched transplant, weight has not been placed on these
results.
Explanted heart showed accelerated coronary and intramyocardial
vasculopathy, leading to diffuse multifocal ischaemic cardiomyopathy
with subsequent myopathic features.
Discussion
This is the first report of utilization of eculizumab for chronic AMR as
bridge to retransplantation in a heart transplant patient.
Antibody-mediated rejection is both a diagnostic and management
challenge in heart transplantation. Commonly, patients present with
graft dysfunction, elevated DSAs, accelerated coronary artery vascul-
opathy, and endomyocardial biopsies showing an absence of severe
cellular rejection.3 Management strategies are based on aggressive
immunosuppression with IVIG, plasmapheresis, and high-dose corti-
costeroids, as well as second-line therapy including rituximab and
bortezomib. Tocilizumab, an anti-interleukin-6 receptor antibody,
has been shown to reduce complement components C3 and C4, and
may have some utility in AMR. Eculizumab, specifically binding to ter-
minal complement C5, acting at a late stage in the complement cas-
cade and preserving the proximal components of the complement
system.
Targeting of complement-binding antibodies was key to managing
AMR in this patient. This guided the use of eculizumab which targets
complement despite elevated DQ7 levels as the case highlights.
Figure 1 Timeline of DQ7 antibody MFI and relevant treatments.




























































Eculizumab has been demonstrated as a successful treatment for
AMR in renal transplantation4,5 but this case represents, to the best
of our knowledge, the first use for the management of chronic AMR.
Despite not having complete resolution of DSA titres, but in context
of definite clinical response, identification and quantification of com-
plement-binding DSAs has a significant role in both diagnosis and
management of AMR. The use of eculizumab as treatment is reason-
able short to medium term to prevent the need for retransplantation
in patients without concurrent allograft vasculopathy or diastolic dys-
function. Whether, if used prior to onset of significant allograft vascul-
opathy eculizumab could be considered as a treatment, rather than
just a bridge to transplantation, is yet to be explored. In this case, con-
cern about ongoing diastolic dysfunction, significant coronary allo-
graft vasculopathy and the implications of long-term heavy
immunosuppressive therapy for a young patient prompted relisting
for transplantation, with an excellent response to retransplantation.
This case demonstrates the importance of DQ7 matching; how-
ever, the broader implications for transplanting patients mismatched
at DQ7 are not clear. Our experience demonstrates this should be
taken with caution, only when absolutely necessary, and consider-
ation to de-sensitisation therapies prior with follow-in IVIG and
plasmapheresis following initial transplantation should be given if the
recipient has imminent risk of death.
In eligible patients with chronic AMR, retransplantation is the only
cure but stabilization to permit relisting is critical. For this patient,
eculizumab stabilized graft function and functional class, allowing time
on the list for a suitable match to be found.
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